All News

Addressing the opioid crisis will require a strong, multifaceted approach that includes efforts to prevent addiction before it begins. By passing the NOPAIN Act, Congress can seize the win-win opportunity to reduce unnecessary exposure to opioids, while protecting—and expanding—a patient’s right to choose their own care.

Davey Daniel, MD, chief medical officer, OneOncology, speaks on the knowledge, infrastructure, and payer-related barriers that are limiting the use of genomic testing in the management of patients with lung cancer.

Research shows that only 1.05% of US emergency department (ED) visits included HIV testing in 2018 and that HIV testing rates varied by race, age group, and region.

Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

Researchers found that implementing an incremental schedule for hemodialysis in patients with residual kidney disease produced similar clinical outcomes and significant savings for health systems compared with hemodialysis administered on a more traditional schedule.

The association between higher disease activity risk of cardiovascular (CV) events was strongest during the first 6 months of follow-up, the study found.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.

The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.

Predictive models can help find high-risk patients with asthma and manage them proactively, but prior models miss the highest-risk patients and may mislabel low-risk patients.

The study was conducted because information on the relationship between eosinophilic esophagitis (EOE) symptoms and biologic findings are limited, so researchers looked at the long-term effects of esophageal dilation, including patient-reported outcome (PRO) measures.

Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, spoke on the design of the 2 phase 4 real-world studies investigating severity and quality of life impact of tildrakizumab for the treatment of psoriasis.

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022.

The researchers warned that while the data revealed into rosacea subtypes, their findings should be interpreted with caution due to a high degree of heterogeneity.

Despite technological advancements, there are still many factors that can cause specimens for comprehensive genomic profiling (CGP) testing to become compromised, potentially leading to inaccurate prognostic results, according to a recent webinar.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Bristol Myers Squibb settles lawsuit on conspiring to block generic competition to HIV drugs; FDA grants emergency use authorization to a novel breath test that can detect COVID-19 within 3 minutes; health savings accounts (HSAs) are being used less effectively by minority and low-income populations.

A recent study on Hispanics/Latinos in the United States found that lower potassium intake and higher sodium-to-potassium ratios may be more predictive of chronic kidney disease risk.

This new literature review explored the potential to enhance management for type 1 diabetes (T1D) through the adoption of physiological parameters measured by wearable and sensor-enabled health-related technology.

Delayed diagnosis of wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) results in inappropriate treatments prior to diagnosis and worse clinical outcomes after diagnosis.

A recent study found that budesonide-based triple therapy was just as effective as fluticasone-based triple therapy, with less incidence of death and severe pneumonia.

Results of the phase 3 ALPINE trial provided found zanubrutinib was superior to ibrutinib in overall response rate.

The Institute for Clinical and Economic Review (ICER) and researchers at NORC at the University of Chicago released a white paper that looks at the future of affordability and sustainability of drug development for rare disease through the lens of 4 policy proposals.

For adults with a history of depression, chronic cough can increase the risk of recurrent depressive events, a study found.

While studies have explored risks among patients with multiple myeloma, recent research is the first to compare cardiovascular mortality risk in multiple myeloma to that of the general population.

McKinsey, hired by the FDA to consult on the opioid epidemic, also provided similar services to Purdue Pharma; the CDC extends its mask mandate for airplane passengers and staff; United Kingdom researchers investigate liver disease spike among children.

Accenture’s 2021 report, “The Future Is Now: How to Drive Precision Oncology Adoption," adds to the chorus calling for greater sharing of data and improved standardization, so that academic centers and community practices alike can continually improve data sets used worldwide.

Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.